Ernexa Therapeutics Inc.ERNAEarnings & Financial Report
Ernexa Therapeutics Inc. is a US-based clinical-stage biotechnology company focused on developing novel targeted therapies for rare neuroendocrine, metabolic, and related rare diseases with high unmet medical needs. It operates in the biopharmaceutical sector, prioritizing advancement of treatment candidates for underserved patient populations.
Revenue
$0
Gross Profit
$0
Operating Profit
$-8.3M
Net Profit
$-7.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.49
Ernexa Therapeutics Inc. Q3 FY2022 Financial Summary
Ernexa Therapeutics Inc. reported revenue of $0 for Q3 FY2022, with a net profit of $-7.3M (up 91.5% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $8.3M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2022 |
Ernexa Therapeutics Inc. Annual Revenue by Year
Ernexa Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $582.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $582.0K |
Ernexa Therapeutics Inc. Quarterly Revenue & Net Profit History
Ernexa Therapeutics Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $1.0K | — | N/A | N/A |
| Q3 FY2024 | $487.0K | +854.9% | $-26.6M | -5462.8% |
| Q2 FY2024 | $47.0K | — | $-5.5M | -11763.8% |
| Q1 FY2024 | $47.0K | — | $-6.6M | -14142.6% |
| Q3 FY2023 | $51.0K | — | $-5.6M | -10962.7% |
| Q1 FY2023 | $0 | — | $-5.4M | N/A |
| Q3 FY2022 | $0 | — | $-7.3M | N/A |
Income Statement
| Q3 2022 | Q1 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $51000 | $47000 | $47000 | $487000 | $1000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 854.9% | N/A |
Balance Sheet
| Q3 2022 | Q1 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|
| Assets | $20.9M | $15.1M | $52.2M | $49.7M | $46.5M | $7.7M | $5.3M |
| Liabilities | $12.1M | $7.7M | $48.7M | $53.1M | $55.0M | $53.1M | $3.6M |
| Equity | $8.8M | $7.4M | $3.6M | $-3.4M | $-8.5M | $-45.4M | $1.7M |
Cash Flow
| Q3 2022 | Q1 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-6.1M | $-6.0M | $-5.8M | $-3.7M | $-2.3M | $-6.3M | $-15.8M |